51˶

Vitamin D for Neuropathy; Good & Bad News for CAR-T; New Labeling for Surgical Mesh

— News, features, and commentary about cancer-related issues

MedpageToday
Onco Break over a computer rendering of a cancer cell.

Vitamin D supplementation may help lower the risk of in patients treated with paclitaxel. (Journal of the National Comprehensive Cancer Network)

At the same prostate-specific antigen level, Black men have a than white men. (Cancer)

A new kind of chimeric antigen receptor (CAR) T cell called have shown promise for reaching cancer-associated proteins that evade immunotherapy and possibly expand use of CAR T-cell therapy to a broader range of cancers. (Nature)

CAR T cells also may , potentially causing complications during treatment. (Nature)

Women who received were 30% more likely to undergo breast cancer screening. (American Cancer Society, American Journal of Preventive Medicine)

Artificial intelligence (AI) has a central role in a new type of designed to increase precision, enhance patient comfort, and reduce side effects. (Henry Ford Health System)

A new scientific review traces the pathway that take to increase a person's risk of cancer. (University of Miami Miller School of Medicine, JAMA Oncology)

Bayer will , copanlisib (Aliqopa), from the U.S. market, following disappointing results from a phase III trial in non-Hodgkin lymphoma. (Endpoints News)

Reinforcing the role that exposure to , a new study showed that almost a third of non-melanoma skin cancer deaths involve people who work in the sun. (CNN)

Amazon announced a : a discount on the retailer's subscription-based One Medical healthcare service.

The FDA of pembrolizumab (Keytruda) for first-line treatment of HER2-positive gastric/gastroesophageal junction cancer to stipulate use in patients with a PD-L1 expression combined positive score ≥1.

The agency also updated labeling for certain types of , stating that "the safety and effectiveness of surgical mesh in breast surgery, including in augmentation or reconstruction, has not been determined by the FDA."

  • author['full_name']

    Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined 51˶ in 2007.